Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M

Jaguar Health, Inc.

2026-Q1 EPS reported -$13.60 vs consensus -$2.08 ▼ miss (-553.6%)

Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.
Product revenue $1.2M, down 45% YoY; Mytesi/Canalevia-CA1 rights licensed to Future Pak in Jan 2026.
Net loss attributable to common stockholders $7.0M, improved 33% from $10.5M loss in Q1 2025.
Non-GAAP recurring EBITDA loss $5.1M, improved 48% from $9.7M loss a year ago.
Company to present crofelemer data for rare-disease intestinal failure at ESPGHAN June 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jaguar Health, Inc. reported first quarter 2026 results: revenue $20,272, net income $(7,015), EPS $(13.60).

Period: first quarter 2026
Revenue: $20,272
Net income: $(7,015)
EPS: $(13.60)
Result: reported results

Exact text from the filing

per share amounts) 2026 2025 $ change % change License and grant revenue, net $ 19,068 $ 43 19,025 44244 % Product revenue, net 1,204 2,171 (967 ) -45 % Total revenue, net $ 20,272 $ 2,214 18,058 816 % Income (loss) from operations $ 10,182 $ (9,421 ) 19,602 208 % Net loss attributable to common stockholders $ (7,015 ) $ (10,464 ) 3,449 33 % Net loss per

View on SEC.gov

12 earnings releases filed in the last 30 days. Browse all earnings releases →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-232722

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.